BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28672049)

  • 21. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
    Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histopathological diagnosis and prognostic factors in adrenocortical carcinoma.
    Aiba M; Fujibayashi M
    Endocr Pathol; 2005; 16(1):13-22. PubMed ID: 16000842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
    Kiiveri S; Liu J; Arola J; Heikkilä P; Kuulasmaa T; Lehtonen E; Voutilainen R; Heikinheimo M
    Mol Cell Endocrinol; 2005 Apr; 233(1-2):47-56. PubMed ID: 15767045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations.
    Duregon E; Rapa I; Votta A; Giorcelli J; Daffara F; Terzolo M; Scagliotti GV; Volante M; Papotti M
    Hum Pathol; 2014 Aug; 45(8):1555-62. PubMed ID: 24890943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Clinicopathological Analysis of Asian Patients with Adrenocortical Carcinoma: A Single-Center Experience.
    Tsai WH; Dai SH; Lee CC; Chien MN; Zeng YH
    Curr Oncol; 2023 Apr; 30(4):4117-4125. PubMed ID: 37185426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.
    Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB
    Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma.
    Kim Y; Margonis GA; Prescott JD; Tran TB; Postlewait LM; Maithel SK; Wang TS; Evans DB; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem AI; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Poultsides GA; Pawlik TM
    JAMA Surg; 2016 Apr; 151(4):365-73. PubMed ID: 26676603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DAX1 Overexpression in Pediatric Adrenocortical Tumors: A Synergic Role with SF1 in Tumorigenesis.
    de Sousa GR; Soares IC; Faria AM; Domingues VB; Wakamatsu A; Lerario AM; Alves VA; Zerbini MC; Mendonca BB; Fragoso MC; Latronico AC; Almeida MQ
    Horm Metab Res; 2015 Aug; 47(9):656-61. PubMed ID: 25985323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adrenocortical Cancer: A 20-Year Experience of a Single Referral Center in Prognosis and Outcomes.
    Parianos C; Kyriakopoulos G; Kostakis ID; Nasiri-Ansari N; Aggeli C; Dimitriadi A; Angelousi A; Papavassiliou AG; Kaltsas GA; Zografos G; Kassi E
    Horm Metab Res; 2021 Nov; 53(11):709-716. PubMed ID: 34740271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma.
    Poli G; Ruggiero C; Cantini G; Canu L; Baroni G; Armignacco R; Jouinot A; Santi R; Ercolino T; Ragazzon B; Assie G; Mannelli M; Nesi G; Lalli E; Luconi M
    J Clin Endocrinol Metab; 2019 May; 104(5):1712-1724. PubMed ID: 30476173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
    Creemers SG; van Koetsveld PM; van Kemenade FJ; Papathomas TG; Franssen GJ; Dogan F; Eekhoff EM; van der Valk P; de Herder WW; Janssen JA; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2016 Sep; 23(9):727-37. PubMed ID: 27535174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discerning malignancy in adrenocortical tumors: are molecular markers useful?
    Wachenfeld C; Beuschlein F; Zwermann O; Mora P; Fassnacht M; Allolio B; Reincke M
    Eur J Endocrinol; 2001 Sep; 145(3):335-41. PubMed ID: 11517015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Adrenocortical cancer: morphological variants, immunohistochemical characteristics].
    Tkachuk AV; Tertychnyi AS; Beltsevich DG; Roslyakova AA; Belousov PV; Selivanova LS
    Arkh Patol; 2021; 83(3):10-18. PubMed ID: 33822549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours.
    Schmitt A; Saremaslani P; Schmid S; Rousson V; Montani M; Schmid DM; Heitz PU; Komminoth P; Perren A
    Histopathology; 2006 Sep; 49(3):298-307. PubMed ID: 16918977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.
    Fenske W; Völker HU; Adam P; Hahner S; Johanssen S; Wortmann S; Schmidt M; Morcos M; Müller-Hermelink HK; Allolio B; Fassnacht M
    Endocr Relat Cancer; 2009 Sep; 16(3):919-28. PubMed ID: 19465749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virilising adrenocortical tumours in children.
    Bonfig W; Bittmann I; Bechtold S; Kammer B; Noelle V; Arleth S; Raile K; Schwarz HP
    Eur J Pediatr; 2003 Sep; 162(9):623-8. PubMed ID: 12811553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen receptor expression in adrenocortical carcinoma.
    Shen XC; Gu CX; Qiu YQ; Du CJ; Fu YB; Wu JJ
    J Zhejiang Univ Sci B; 2009 Jan; 10(1):1-6. PubMed ID: 19198016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 Stabilization induces cell growth inhibition and affects IGF2 pathway in response to radiotherapy in adrenocortical cancer cells.
    Sampaoli C; Cerquetti L; Gawhary RE; Bucci B; Amendola D; Marchese R; Misiti S; Novelli G; Toscano V; Stigliano A
    PLoS One; 2012; 7(9):e45129. PubMed ID: 23028800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of adiponectin and leptin receptors in adrenal incidentaloma patients with subclinical hormone secretion.
    Babińska A; Pȩksa R; Świa Tkowska-Stodulska R; Wiśniewski P; Sworczak K
    Cancer Biomark; 2018; 22(2):325-332. PubMed ID: 29689708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
    Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
    Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.